Health
FDA Permits Marketing of First SARS-CoV-2 Diagnostic Test Using Traditional Premarket Review Process – FDA.gov
BioFire Diagnostics LLC granted De Novo for its BioFire Respiratory Panel 2.1.
For Immediate Release:
March 17, 2021
Today, the U.S. Food and Drug Administration granted marketing authorization of the BioFire Respiratory Panel 2.1 (RP2.1), a diagnostic test for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of COVID-19 and other respiratory tract infections. The diagnostic test, which had an Emergency Use Authorization (EUA), was granted marketing…
-
Noosa News19 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
General22 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News18 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General22 hours agoDisloyal far-left breakaways are coming for Labor